Shots: The P-III ARIEL3 study results involves assessing of Rubraca (rucaparib, 600mg, bid) vs PBO in 564 patients in a ratio (2:1) with platinum-sensitive recurrent ovarian cancer including patients with […]readmore
Tags : (Rucaparib)
Shots: Clovis Oncology’s Rubraca (rucaparib) enters in EU with its first launch in Germany and is approved for both treatment and maintenance treatment of ovarian cancer in women The launch […]readmore
Shots: The companies enter into an agreement to jointly evaluate safety & efficacy of Alkermes’ ALKS 4230 in combination with Clovis Oncology’s Rucaparib & Lucitanib with equal cost sharing in […]readmore
Shots: The approval is based on P-III ARIEL3 study results assessing Rubraca (600mg, bid) vs PBO in 564 women in a ratio (2:1) with a recurrent epithelial ovarian, fallopian tube or primary […]readmore